NEW YORK, Feb. 28 -Large Scale Biology and the University of Arkansas for Medical Sciences in Little Rock, Ark., have announced an agreement to manufacture therapeutic antibodies to drugs of abuse, the company said today.
Under the agreement, LSBC will first produce an antibody target for the street drug phencyclidine, also known as "angel dust" and PCP.
Michael Owens, who is the director of UAMS; center for alcohol and drug abuse studies, chose LSBC for the production of the antibody. The contract will be financed by National Institute on Drug Abuse grants that fund Owens' research. Owens group has demonstrated through preclinical studies on animals that a monoclonal antibody has potential use for PCP abusers, according to LSBC.
For more information, see the company statement.